Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead clinical candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes VY1706, tau silencing gene therapy in preclinical trial for treatment of alzheimer's disease; SOD1 silencing gene therapy program for the treatment of ALS in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company also develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report) and Skye Bioscience...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VYGR	$4.18	+2.20%	280.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VYGR	$4.18	+2.2%	280.21K
3
4
5
6

VYGR

VYGR

No Data Available

Get Voyager Therapeutics Inc. Data in Excel

Get Voyager Therapeutics Inc. Data in Excel